The effect of metoclopramide on gastric emptying of solid meals

Hancock, Brian; Bowen-Jones, E.; Dixon, R.; Dymock, I. W.; Cowley, David J.

doi:10.1136/gut.15.6.462

Cited by 54 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In nondiabetic subjects it is known to increase the strength of gastric contractions and to accelerate gastric emptying measured either radiologically (Kreel, 1970) or by dye-dilution technique (Connell and George, 1969). The drug has also been shown to reduce gastric stasis associated with surgical vagotomy (Hancock et al, 1974;Metzger et al, 1976). Metoclopramide is thought to act by enhancing the local effect of acetylcholine on gastric smooth muscle (Eismer, 1968), perhaps by increasing the actual amount of acetylcholine at post-ganglionic nerve endings (Hay, 1975).…”

Section: Discussionmentioning

confidence: 99%

Gastric emptying in diabetic autonomic neuropathy.

Campbell¹,

Heading²,

Tothill³

et al. 1977

Gut

142

View full text Add to dashboard Cite

SUMMARY Gastric emptying was studied in 12 diabetic patients, six with and six without objective evidence of autonomic neuropathy and in 20 non-diabetic controls, using a double isotope scintiscanning technique which differentiated between solid and liquid emptying. Three patients with autonomic neuropathy exhibited gastric stasis, although this was detected by conventional radiology in only one. Neither the patients with stasis nor those without exhibited abnormally rapid early gastric emptying. In patients without stasis, the normal differentiation between solid and liquid emptying was impaired, suggesting an abnormality of antral peristalsis not attributable to vagal denervation. Both intravenous and oral metoclopramide produced symptomatic improvement in two patients with gastric stasis and restored their gastric emptying to normal.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastric emptying in diabetic autonomic neuropathy.

Campbell¹,

Heading²,

Tothill³

et al. 1977

Gut

142

View full text Add to dashboard Cite

show abstract

“…Naturally, we may hypothesize this lack of evidence of a significant pharmacological ac tivity to be due to the rather limited number of patients and to the variability in the ileal transit times observed. It is not unlikely that -at least with the dosage employed in our study -the drug may exert its prokinetic effect mainly in conditions of reduced intes tinal propulsive activity, as already de scribed for metoclopramide [16,17], Cisa pride, in fact, stimulates intestinal motility by enhancing the physiological mechanisms; it is therefore possible that its pharmacologi cal stimulus in normal patients may not sig nificantly improve the transit time any fur ther. In conclusion, we believe cisapride to be a valid alternative to traditional proki netic agents in the treatment of disorders associated with alterations in gastric empty ing.…”

Section: Discussionmentioning

confidence: 99%

Effect of Cisapride on Gastric Emptying and Heal Transit Time of Balanced Liquid Meal in Healthy Subjects

Lazzaroni

Sangaletti

Porro³

1987

Digestion

View full text Add to dashboard Cite

Cisapride is a new prokinetic gastrointestinal agent which has been shown to be able to increase gastric emptying and intestinal transit time in experimental animals and in patients with preexisting motility alterations. Up to now, however, clinical research evaluating the activity of the drug in healthy subjects is very limited. We have therefore undertaken a placebo-controlled study to simultaneously investigate the effect of cisapride (20 mg p.o.) on gastric emptying and intestinal transit time of a balanced liquid meal in 9 healthy volunteers. Median gastric half-time was 60 min after cisapride, as compared to 73 min after placebo (p < 0.05). Intestinal transit time was similar after cisapride (75 min) or after placebo (105 min). These data confirm that cisapride significantly increases the speed of gastric emptying also in normal subjects. The lack of effect on intestinal transit could be explained by the interindividual variation observed in our experiments.

show abstract

“…Metoclopramide, dom peridone and cisapride have been used in the treatment of non-ulcer dyspepsia, because of their stimulatory effect on gastric emptying in animals and man (6)(7)(8)(9)(10)(11). Therefore, in esti mating the effect on non-ulcer dyspepsia, it is important to know the stimulatory effect of HSR-803 not only on the gastrointestinal con tractions but also on the gastrointestinal func tions.…”

mentioning

confidence: 99%

Stimulatory Effect of N-(4-(2-(Dimethylamino)-ethoxy)benzyl)-3,4-Dimethoxybenzamide Hydrochloride(HSR-803)on Normal and Delayed Gastrointestinal Propulsion.

et al. 1991

View full text Add to dashboard Cite

ABSTRACT-To estimate the effect of a new gastroprokinetic agent, N-[4-[2 (dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide hydrochloride (HSR-803), on non-ulcer dyspepsia, the influence of HSR-803 on gastrointestinal propulsion was assayed in dogs, rats and mice in comparison with some gastroprokinetic agents. HSR-803 (30 mg/kg, p.o.) significantly enhanced gastric emptying in dogs, and it sig nificantly improved the delayed gastric emptying induced by dopamine (0.4 mg/kg, i.p.) and morphine (1 mg/kg, s.c.) in rats. Metoclopramide (30 mg/kg, p.o.) also sig nificantly restored the dopamine-induced delay, but at a dose of 10 mg/kg, p.o., it en hanced the morphine-induced delay in gastric emptying in rats. HSR-803 (10 100 mg/kg, p.o.) increased small intestinal transit in mice in a dose-dependent manner, and the effect was abolished by atropine (0.3 mg/kg, i.p.). Metoclopramide also in creased small intestinal transit, but domperidone and cisapride had no effect. In de layed small intestinal transit in mice, HSR-803 (10-100 mg/kg, p.o.) improved the morphine (0.3 mg/kg, s.c.)-induced delay in a dose-dependent manner. In conclusion, because of the promotion of normal and delayed gastrointestinal propulsion, HSR-803 seems to be a promising gastroprokinetic agent for the treatment of non-ulcer dyspep sia. The action of HSR-803 is likely to be exerted through cholinergic stimulation.It has been reported that a new gastropro kinetic agent, HSR-803, stimulates gastrointes tinal motility in conscious dogs, probably through dopamine D2 receptor (D2) blocking and anti-acetylcholinesterase (anti-AChE) ac tivities (1). Several gastroprokinetic agents, metoclopramide and domperidone are known to be D2 antagonists, and reported to have weak anti-AChE activity (1-3). A newly de veloped gastroprokinetic agent, cisapride, also has an anti-D2 action (4). The D2 blocking activity of HSR-803 was weaker than that of metoclopramide, domperidone and cisapride, while anti-AChE activity was more potent than that of metoclopramide and domperidone (5). Thus the pharmacological profile of HSR 803 was expected to differ from that of meto clopramide and domperidone.One of, the gastrointestinal disorders, non ulcer dyspepsia having symptoms of discom fort in the epigastrium, fullness in the abdo men, nausea and emesis is mainly due to de

show abstract

The effect of metoclopramide on gastric emptying of solid meals

Cited by 54 publications

References 12 publications

Gastric emptying in diabetic autonomic neuropathy.

Gastric emptying in diabetic autonomic neuropathy.

Effect of Cisapride on Gastric Emptying and Heal Transit Time of Balanced Liquid Meal in Healthy Subjects

Stimulatory Effect of N-(4-(2-(Dimethylamino)-ethoxy)benzyl)-3,4-Dimethoxybenzamide Hydrochloride(HSR-803)on Normal and Delayed Gastrointestinal Propulsion.

Contact Info

Product

Resources

About